Skip to main content

Carbohydrate antigen 242 highly consists with carbohydrate antigen 19-9 in diagnosis and prognosis of colorectal cancer: study on 185 cases

Medical Oncology volume 29, pages 1030–1036 (2012)Cite this article

Abstract

The objective of the study was to compare the clinical value of preoperative serum carbohydrate antigen 19-9 (CA19-9) and carbohydrate antigen 242 (CA242) in diagnosis and prognosis for 5-year recurrence-free survival (RFS) in patients with colorectal cancer (CRC). Preoperative serum CA19-9 and CA242 concentrations were detected by C12 protein chip diagnostic system in 185 patients with CRC, and informative data were collected during 5-year follow-up periods. The value of CA19-9 and CA242 in diagnosis and prognosis for 5-year RFS as well as their consistencies and correlations were comparatively analyzed. The sensitivities of CA19-9 and CA242 were only 19.5 and 20%, respectively; the efficiencies of two TMs were 53.9 and 54.2%, respectively; and two TMs increased significantly with advancing clinical stages (P < 0.0001). Preoperative CA19-9 and CA242 levels correlated with stage (r, 0.411 and 0.408) and CEA concentration (r, 0.553 and 0.630). The concentrations of two TMs closely correlated with each other (r = 0.829), and two TMs had a very strong consistency in diagnosis (κ = 0.931). Among 88 of 185 cases with complete follow-up information on RFS, patients with positive preoperative serum CA19-9 or CA242 had higher 5-year recurrent rates (72.2% vs. 44.3%, P = 0.034; 76.5% vs. 43.7%, P = 0.015) and reduced median RFS (14 vs. 36 months, 12 vs. 36 months) compared with those with negative TMs. The consistency of predicting prognosis for RFS of two TMs was extremely strong (κ = 0.964). ROC curves analysis showed that CA242 test performed better than CA19-9 test (AUC, 0.648 vs. 0.605). Univariate analysis showed that preoperative serum status of both TMs was correlated with 5-year RFS (P < 0.05), whereas multivariate Cox regression model analysis revealed that none of them were independent prognostic factors for RFS. Both CA19-9 and CA242 had strong consistencies in diagnosis and prognosis for predicting 5-year RFS. CA242 demonstrated superior value to CA19-9 in CRC.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3

Abbreviations

CRC:

Colorectal cancer

CA19-9:

Carbohydrate antigen 19-9

CA242:

Carbohydrate antigen 242

TM:

Tumor marker

RFS:

Recurrence-free survival

C12:

12 Tumor-marker protein chip system

IQR:

Interquartile range

PPV:

Positive predictive value

NPV:

Negative predictive value

CI:

Confidence interval

RR:

Relative risk

ROC:

Receiver operating characteristic

AUC:

Area under curve

TPA:

Tissue polypeptide antigen

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.

    PubMed  Article  Google Scholar 

  2. Ministery of Health of the People’s Republic of China. Mortality rate of 10 main malignant neoplasms from 2004 to 2005. http://www.moh.gov.cn/publicfiles/business/htmlfiles/zwgkzt/ptjnj/year2009/t-9.htm.

  3. Carpelan-Holmström M, Haglund C, Lundin J, Alfthan H, Stenman UH, Roberts PJ. Independent prognostic value of preoperative serum markers CA 242, specific tissue polypeptide antigen and human chorionic gonadotrophin beta, but not of carcinoembryonic antigen or tissue polypeptide antigen in colorectal cancer. Br J Cancer. 1996;74(6):925–9.

    PubMed  Article  Google Scholar 

  4. Levy M, Visokai V, Lipska L, Topolcan O. Tumor markers in staging and prognosis of colorectal carcinoma. Neoplasma. 2008;55(2):138–42.

    PubMed  CAS  Google Scholar 

  5. Du J, Li Y, Li J, Zheng J. Polycomb group protein Bmi1 expression in colon cancers predicts the survival. Med Oncol. 2010;27(4):1273–6.

    PubMed  Article  CAS  Google Scholar 

  6. Yang XQ, Yan L, Chen C, Hou JX, Li Y. Application of C12 multi-tumor marker protein chip in the diagnosis of gastrointestinal cancer: results of 329 surgical patients and suggestions for improvement. Hepatogastroenterology. 2009;56(94–95):1388–94.

    PubMed  CAS  Google Scholar 

  7. Magnani JL, Nilsson B, Brockhaus M, Zopf D, Steplewski Z, Koprowski H, Ginsburg V. A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J Biol Chem. 1982;257(23):14365–9.

    PubMed  CAS  Google Scholar 

  8. Kim HJ, Yu MH, Kim H, Byun J, Lee C. Noninvasive molecular biomarkers for the detection of colorectal cancer. BMB Rep. 2008;41(10):685–92.

    PubMed  Article  CAS  Google Scholar 

  9. Yamashita K, Watanabe M. Clinical significance of tumor markers and an emerging perspective on colorectal cancer. Cancer Sci. 2009;100(2):195–9.

    PubMed  Article  CAS  Google Scholar 

  10. Papk IJ, Choi GS, Jun SH. Prognostic value of serum tumor antigen CA19-9 after curative resection of colorectal cancer. Anticancer Res. 2009;29(10):4303–8.

    Google Scholar 

  11. Svobodova S, Topolcan O, Holubec L Jr, Levy M, Pecen L, Svacina S. Parameters of biological activity in colorectal cancer. Anticancer Res. 2011;31(1):373–8.

    PubMed  CAS  Google Scholar 

  12. Haglund C, Lundin J, Kuusela P, Roberts PJ. CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19–9, CA 50 and CEA. Br J Cancer. 1994;70(3):487–92.

    PubMed  Article  CAS  Google Scholar 

  13. Kuusela P, Haglund C, Roberts PJ. Comparison of a new tumour marker CA 242 with CA 19–9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases. Br J Cancer. 1991;63(4):636–40.

    PubMed  Article  CAS  Google Scholar 

  14. Johansson C, Nilsson O, Baeckström D, Jansson EL, Lindholm L. Novel epitopes on the CA50-carrying antigen: chemical and immunochemical studies. Tumour Biol. 1991;12(3):159–70.

    PubMed  Article  CAS  Google Scholar 

  15. Johansson C, Nilsson O, Lindholm L. Comparison of serological expression of different epitopes on the CA50-carrying antigen CanAg. Int J Cancer. 1991;48(5):757–63.

    Google Scholar 

  16. Spila A, Ferroni P, Cosimelli M, D’Alessandro R, Carone MD, Aloe S, Tedesco M, Mancini R, Casale V, Carlini S, Casciani CU, Roselli M, Guadagni F. Evaluation of the CA 242 tumor antigen as a potential serum marker for colorectal cancer. Anticancer Res. 1999;19(2B):1363–8.

    Google Scholar 

  17. Spila A, Ferroni P, Cosimelli M, D’Alessandro R, Abbolito MR, Mariotti S, Aloe S, Carone MD, Graziano F, Tedesco M, Martini F, Mancini R, Stigliano V, Roselli M, Guadagni F. Comparative analysis of CA 242 and CA 19-9 serum tumor markers in colorectal cancer patients. A longitudinal evaluation. Anticancer Re. 2001;21(2B):1263–70.

    Google Scholar 

  18. Carpelan-Holmström M, Haglund C, Kuusela P, Järvinen H, Roberts PJ. Preoperative serum levels of CEA and CA 242 in colorectal cancer. Br J Cancer. 1995;71(4):868–72.

    PubMed  Article  Google Scholar 

  19. Kim SB, Fernandes LC, Saad SS, Matos D. Assessment of the value of preoperative serum levels of CA 242 and CEA in the staging and postoperative survival of colorectal adenocarcinoma patients. Int J Biol Markers. 2003;18(3):182–7.

    PubMed  CAS  Google Scholar 

  20. Cardoso ML, Fernandes LC, Kim SB, Matos D. Relationship between peripheral and mesenteric serum levels of CEA and CA 242 with staging and histopathological variables in colorectal adenocarcinoma. Acta Cir Bras. 2009;24(5):405–10.

    PubMed  Article  Google Scholar 

  21. Nicolini A, Ferrari P, Duffy MJ, Antonelli A, Rossi G, Metelli MR, Fulceri F, Anselmi L, Conte M, Berti P, Miccoli P. Intensive risk-adjusted follow-up with the CEA, TPA, CA19.9, and CA72.4 tumor marker panel and abdominal ultrasonography to diagnose operable colorectal cancer recurrences: effect on survival. Arch Surg. 2010;145(12):1177–83.

    Google Scholar 

Download references

Acknowledgments

Supported by the grants supporting New Strategies to Treat Peritoneal Carcinomatosis from Hubei Sciences and Technology Beureau (2008BCC011, 2060402-542), Jingmen Science and Technology Planning Project (No. 2010S21), the Scholarship Award for Excellent Doctoral Student granted by Ministry of Education (2010), and the Science Fund for Creative Research Groups of the National Natural Science Foundation of China (No. 20621502 and 20921062).

Author information

Affiliations

  1. Department of Oncology, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory on Tumor Biological Behaviors and Hubei Cancer Clinical Study Center, No 169 Donghu Road, 430071, Wuhan, China

    Xue-Qin Yang, Chuang Chen, Chun-Wei Peng, Shao-Ping Liu & Yan Li

  2. Medical School of Jingchu University of Technology, 448000, Jingmen, China

    Xue-Qin Yang

Authors
  1. Xue-Qin Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chuang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chun-Wei Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shao-Ping Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yan Li.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Yang, XQ., Chen, C., Peng, CW. et al. Carbohydrate antigen 242 highly consists with carbohydrate antigen 19-9 in diagnosis and prognosis of colorectal cancer: study on 185 cases. Med Oncol 29, 1030–1036 (2012). https://doi.org/10.1007/s12032-011-9967-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-011-9967-z

Keywords

  • Colorectal cancer
  • Carbohydrate antigen 19-9
  • Carbohydrate antigen 242
  • Diagnosis
  • Recurrence-free survival
  • Comparative analysis